When to Order Genetic Testing

Indications for Genetic Kidney Disease Panel:

1. Early-onset CKD (age <30 years):
   • No diabetes, hypertension, or other obvious secondary cause
   • Proteinuria or hematuria on screening
   • Family history of CKD or ESRD
   • Diagnosis clarification to differentiate primary from secondary disease
2. Familial renal disease:
   • Multiple family members with CKD/ESRD
   • Inheritance pattern (autosomal dominant, autosomal recessive, X-linked)
   • Could inform genetic counseling, surveillance of unaffected relatives
3. Atypical presentation:
   • Rapidly progressive CKD despite seemingly modest proteinuria
   • FSGS refractory to treatment (genetic variants in NPHS2, ACTN4, INF2)
   • Thin basement membrane disease (uncertain prognosis)
   • AKI with minimal systemic features (possible hereditary nephritis like Alport)
4. Syndromic kidney disease:
   • Kidney disease + deafness (suspect Alport syndrome)
   • Kidney disease + eye findings (Alport, anterior lenticonus)
   • Kidney disease + skeletal abnormalities
   • Kidney disease + neurologic involvement
5. Monogenic vs. polygenic distinction:
   • If genetic testing positive → informs prognosis, counseling, surveillance
   • If negative → likely polygenic disease; environmental factors dominate

Genetic Testing Panels & Gene Categories

Category 1: Glomerulonephritis-Associated Genes - IgA Nephropathy genes: - CFHR1/CFHR3 deletion (30% of IgAN) - TRAF3IP2, HLADQ2 - Counseling: Family screening, assessment of progression risk

• Lupus-associated genes:
  • C1q deficiency (rare but predisposes to lupus-like disease)
  • Complement pathway mutations
• ANCA-associated vasculitis genes:
  • Rare genetic predisposition; usually environmental trigger
  • SERPINA1 (alpha-1 antitrypsin deficiency rarely associated)

Category 2: FSGS-Associated Genes (Monogenic FSGS) - Podocyte-expressed genes: - NPHS2 (podocin) — most common; autosomal recessive inheritance - ACTN4 (alpha-actinin-4) — autosomal dominant - INF2 (inverted formin 2) — autosomal dominant - TRPC6 (transient receptor potential channel 6) — autosomal dominant - CD2AP, FAT1, KANK1, PCDH19, others

• Prognosis: Genetic FSGS often presents age <20 years; variable progression; steroid-resistant in most cases; no prevention

Category 3: Hereditary Nephritis Genes - COL4A3, COL4A4, COL4A5 (Alport syndrome): - Mutations in type IV collagen genes - X-linked (85%) — males affected; females carriers with variable disease - Autosomal recessive (15%) — affects both sexes equally - Symptoms: Progressive hematuria, proteinuria, then CKD; sensorineural hearing loss; eye findings (anterior lenticonus, retinal flecks) - Prognosis: Males reach ESRD by age 20–50 depending on severity - Counseling: Screen family members; assess for hearing loss, ophthalmology involvement

• Thin Basement Membrane Disease (TBM):
  • COL4A mutations (some), or other undefined genes
  • Usually benign; excellent prognosis
  • Distinguish from early Alport (TBM appearance initially, then progresses)
  • Genetic testing may be inconclusive (mutation not found in 30–50% of TBM cases)

Category 4: Ciliopathy Genes (Autosomal Recessive Polycystic Kidney Disease) - PKHD1, PKD1, PKD2 (cystic kidney disease genes) - Testing clarifies prognosis: ARPKD worse prognosis than ADPKD

Category 5: Metabolic/Transport Gene Disorders - AGXT (primary hyperoxaluria type 1): Oxalate synthesis pathway - Renal Fanconi syndrome genes: SLC34A1 (sodium-phosphate cotransporter), others - Cystinosis genes: CTNS - These allow specific metabolic interventions

Genetic Testing Workflow

Step 1: Clinical Diagnosis Clarification - Is this likely monogenic or polygenic disease? - Age, inheritance pattern, clinical features guide testing

Step 2: Select Appropriate Panel - Broad panels: >100 genes (increasing yield, cost, variants of uncertain significance) - Disease-specific panels: FSGS panel, Alport panel, hereditary nephritis panel (targeted, more interpretable) - Single-gene testing if specific diagnosis suspected

Step 3: Genetic Counseling (Pre-Test) - Discuss purpose, possible findings, implications - Inform patient that testing may find unexpected variants (incidental findings) - Discuss confidentiality, insurance/employment implications - Obtain informed consent

Step 4: Interpret Results - Pathogenic variant: Clearly associated with disease; explains phenotype - Likely pathogenic: High probability of pathogenicity - Variant of uncertain significance (VUS): Cannot determine if pathogenic; requires functional studies or family analysis - Benign/likely benign: Unlikely to cause disease - Negative: No pathogenic variants found (does not exclude genetic disease; may be polygenic or missed by sequencing)

Step 5: Post-Test Counseling - Discuss clinical implications - Outline management/surveillance plan - Address family implications; consider cascade screening

Biology of APOL1

Gene Function: - APOL1 encodes apolipoprotein L1, a component of innate immune system - Antimicrobial role: Protects against African sleeping sickness (Trypanosoma brucei) - Two non-reference variants (G1 and G2 alleles) arose from natural selection for trypanosome resistance in Africa

Epidemiology: - Prevalence in African Americans: 13–14% carry G1/G1, G2/G2, or G1/G2 genotypes (two-risk-allele carriers) - Prevalence in West Africans: 40–50% carry two risk alleles (higher in malaria-endemic regions) - Prevalence in European ancestry: <1% (rare)

APOL1 Risk Alleles & CKD Risk

Genetics: - Two copies of risk allele (high-risk genotype) = G1/G1, G2/G2, or G1/G2 - One copy (heterozygous) = reduced/minimal kidney disease risk - Zero copies (reference/G0) = baseline risk

Kidney Disease Risk with Two APOL1 Risk Alleles: - FSGS: 3–5-fold increased risk - Non-diabetic CKD: 2–3-fold increased risk - Diabetes-associated CKD: 1.5–2-fold increased risk (SGLT2i therapy may modify this) - Lupus nephritis: 2–3-fold increased risk; more severe disease

Penetrance: - Important limitation: Carrying two risk alleles does NOT guarantee kidney disease - 85–90% of African Americans with two risk alleles remain kidney-disease-free throughout life - Other genetic and environmental factors required to trigger disease

Mechanism of APOL1-Mediated CKD

Proposed Pathophysiology (Still Being Elucidated): 1. Podocyte toxicity: APOL1 expression in podocytes; risk variants cause mitochondrial dysfunction 2. Inflammasome activation: NLRP3 inflammasome activation → IL-1β, IL-18 production → inflammatory cascade 3. Autophagy dysfunction: Impaired cellular autophagy → accumulation of damaged organelles 4. Ion channel dysfunction: APOL1 function as ion channel; variants alter channel properties 5. Endothelial injury: Vascular dysfunction → increased glomerular permeability 6. Immune dysregulation: Altered innate immune response

Trigger Events (Likely Required for Disease Manifestation): - Systemic hypertension (key cofactor) - Systemic inflammation (infection, lupus) - Diabetes hyperglycemia - HIV infection (accelerates APOL1-associated CKD) - Environmental toxins - Genetic modifier alleles (polygenic contribution)

Clinical Application: APOL1 Testing & Counseling

Indications for APOL1 Testing: 1. African American with early-onset FSGS: Clarify if APOL1-associated 2. African American with non-diabetic CKD: Risk stratification 3. Reduced kidney donor (African American) with FSGS: Assess recurrence risk in donor (contentious) 4. Family history of ESRD in African American: Risk assessment for relatives 5. Research studies: Enrollment in APOL1-focused intervention trials

Results Interpretation:

Counseling for High-Risk (Two Alleles) Individuals: 1. Risk context: “You carry genetic variants that increase kidney disease risk 3–5-fold, but 85–90% of people with these variants never develop kidney disease.” 2. Modifiable factors: “Hypertension control is especially important for you; keep BP <130/80. Avoid NSAIDs, manage diabetes aggressively.” 3. Screening: “Get annual kidney function tests (creatinine, GFR, urine protein) starting now. Early detection allows treatment to slow progression.” 4. Family implications: “Your siblings/children have 25–50% chance of inheriting risk alleles; they should be screened.” 5. No change in management yet: Standard hypertension/CKD treatment applies; APOL1-targeted therapy not yet available

APOL1-Targeted Research & Future Therapies

Potential Therapeutic Targets: - NLRP3 inflammasome inhibitors: Block downstream inflammatory cascade (early trials) - Mitochondrial protective agents: Improve podocyte energy metabolism - Ion channel modulators: Normalize APOL1 channel function - Autophagy enhancers: Improve cellular debris clearance

Current Clinical Trial Landscape: - Multiple phase 2 trials testing anti-inflammatory and mitochondrial-protective agents in APOL1-associated CKD - No FDA-approved APOL1-targeted therapy yet (as of 2026) - SGLT2 inhibitors show benefit in all CKD, including APOL1-associated (mechanism not fully clear)

Emerging Biomarkers for CKD Progression Prediction

Definition: Biomarkers = measurable biological indicators of disease state, progression risk, or therapy response

suPAR (Soluble Urokinase Plasminogen Activator Receptor)

Discovery & Biology: - Circulating form of uPA receptor; shed by leukocytes in inflammation - Associated with increased glomerular permeability in FSGS - Elevated suPAR levels associated with proteinuria and podocyte dysfunction

Clinical Application: - Prognostic role: Elevated serum suPAR predicts FSGS diagnosis and faster CKD progression - Risk stratification: High suPAR + proteinuria = worse renal outcomes - Limitations: Not specific to FSGS (elevated in other CKD types); cutoff values debated

Current Status: Research tool; not yet widely used in clinical practice; FDA biomarker qualification in progress

NGAL (Neutrophil Gelatinase-Associated Lipocalin)

Discovery & Biology: - Protein released by neutrophils in response to inflammation/injury - Serum and urine levels increase in AKI (early marker, before creatinine rise) - In CKD, NGAL reflects underlying kidney inflammation

Clinical Application: - AKI detection: Elevated within hours of kidney injury (urine NGAL more specific than serum) - CKD progression: Elevated urine NGAL associated with faster GFR decline - Prognosis: Urine NGAL predicts kidney biopsy-proven inflammation severity

Current Status: Clinically available; used in some centers for AKI risk stratification; not standard-of-care for CKD yet

KIM-1 (Kidney Injury Molecule-1)

Discovery & Biology: - Transmembrane protein on proximal tubular epithelium; shed into urine after tubular injury - Reflects tubular epithelial cell damage

Clinical Application: - AKI marker: Early indicator of tubular injury (before creatinine rise) - CKD progression: Elevated urine KIM-1 associated with faster decline - IgA nephropathy: High urine KIM-1 predicts progression in IgAN

Current Status: Research tool; commercial assays becoming available; shows promise for CKD risk stratification

TIMP-2 and IGFBP-7 (Tissue Inhibitor of Metalloproteinases-2 and Insulin-Like Growth Factor-Binding Protein-7)

Discovery & Biology: - Released from tubular epithelium in response to injury - Combination marker predicts AKI risk and mortality

Clinical Application: - AKI risk prediction: (TIMP-2 × IGFBP-7) score stratifies AKI risk in ICU patients - CKD progression: Early studies suggest combined marker predicts CKD progression risk

Current Status: FDA-approved test for AKI risk (Nephros test); not yet integrated into CKD monitoring

MCP-1 (Monocyte Chemoattractant Protein-1 / CCL2)

Discovery & Biology: - Chemokine released by kidney cells in inflammation; recruits monocytes - Elevated in urine in glomerulonephritis and lupus

Clinical Application: - Lupus nephritis activity: Urine MCP-1 predicts disease flare, treatment response - Diabetic nephropathy: Elevated MCP-1 associated with progression - Monitoring tool: May track response to immunosuppression

Current Status: Primarily research tool; some specialized labs offer testing; not routine clinical use

Emerging Panel Approach

Multi-Marker Strategies: - Single biomarkers have limited specificity; combinations improve prediction - Examples: (Creatinine + Cystatin C + Albuminuria + NGAL + KIM-1) → machine learning algorithm for progression risk - Potential to individualize CKD management (e.g., more aggressive therapy if high biomarker panel score)

Definition & Rationale

Pharmacogenomics: Study of how genetic variation influences drug response - Goal: Personalize medication selection and dosing based on patient genetics - In nephrology: Limited but growing applications in CKD therapy

Genetic Variants Affecting CKD Medications

ACE Inhibitor/ARB Response: - ACE insertion-deletion (I/D) polymorphism: III genotype associated with greater albuminuria reduction with ACEi in some studies (inconsistent data) - Clinical application: Limited; ACEi/ARB offered to all CKD patients regardless of genotype - Status: Research level; not used clinically for drug selection

SGLT2 Inhibitor Metabolism: - CYP3A4 and UGT1A4 variants: Affect empagliflozin/dapagliflozin metabolism - Clinical implication: Minimal; standard dosing appropriate for most genetic variants - Status: Not clinically actionable; standard dosing remains

Immunosuppressive Drug Metabolism: - TPMT (thiopurine methyltransferase) variants: Affect azathioprine metabolism - TPMT deficiency → severe toxicity with standard doses - TPMT testing recommended before azathioprine use - ALPL (alkaline phosphatase) variants: Minor role in drug response

NSAIDs & Genetic Risk: - CYP2C8/C9 variants: Affect NSAID metabolism - Clinical implication: High-risk variants associated with NSAID-related AKI - Status: Not standard clinical testing; avoid NSAIDs in CKD regardless of pharmacogenomics

Current Clinical Applications

Testing Recommended (Pre-Treatment): 1. TPMT testing before azathioprine: Identifies deficiency (1 in 300–500 people) that increases toxicity risk 2. Consideration of CYP3A4 status: If using calcineurin inhibitors (variable levels affect dosing)

Not Routinely Recommended: - ACE/ARB genotyping (not predictive enough) - SGLT2i genotyping (standard dosing appropriate) - Beta-blocker genotyping (despite CYP2D6 variants affecting metabolism, clinical benefits override genetic differences)

Complement-Targeted Therapies

Rationale: Complement dysregulation implicated in MPGN, C3GN, post-infectious GN, lupus

Available Agents: 1. C5 inhibitors: - Eculizumab (Soliris): IV monoclonal antibody against C5 - Pegcetacoplan (Empaveli): C3 inhibitor (not C5) - Approval: C3GN, post-infectious GN with rapidly progressive course - Mechanism: Blocks C5a generation and terminal complement cascade

2. C3 inhibitors:
   • Pegcetacoplan: Direct C3 inhibitor; blocks proximal complement cascade
   • Approval: C3GN, post-infectious GN
   • Advantage over C5i: Blocks C3 generation earlier; may be more effective in C3-dominant disease
3. Factor B inhibitors:
   • Iptacopan: Proximal complement pathway inhibitor (Factor B)
   • Status: Recently FDA-approved for lupus nephritis; ongoing trials for other GN
4. Factor H pathway:
   • Iptacopan, danicopan: Factor D inhibitors
   • Pending trials in MPGN, C3GN

Clinical Application by Disease: - Post-Infectious GN: Complement dysregulation documented; C3i or C5i considered if rapidly progressive - C3GN/Membranoproliferative C3GN: Primary indication; C3i preferred if genetic dysregulation confirmed - Lupus Nephritis: Factor B inhibitors (iptacopan) showing benefit in recent trials; monoclonal anti-C3 in development

Prognosis with Targeted Therapy: - Post-infectious GN + C5i: 50–70% achieve hematuria/proteinuria improvement - C3GN + C3i: Variable response; best if diagnosed early before fibrosis - Lupus + Factor B inhibitor: Phase 3 trials showing renal response benefit

Endothelin Receptor Antagonists (ERA)

Mechanism: - Endothelin-1 (ET-1) powerful vasoconstrictor; promotes fibrosis - Era-A and Era-B receptors in glomeruli and tubules - ERAs reduce intraglomerular pressure and anti-fibrotic effects

Agent: - Atrasentan: Non-selective ERA (blocks both ETA and ETB)

Clinical Application: - CKD from hypertension/diabetes: Added to RAS inhibitor + SGLT2i - Indication: Stage 3–4 CKD with albuminuria; slows GFR decline

Clinical Trial Evidence: - SONAR trial (2017): Atrasentan + ACE inhibitor vs. ACEi alone in CKD - 35% reduction in doubling of serum creatinine or ESRD in atrasentan group - Modest fluid retention in some patients

FDA Approval Status: - Approved for CKD with albuminuria (2021) - Used as add-on to ACEi/ARB + SGLT2i for patients with significant albuminuria

Precision Application: - Most effective in patients with active albuminuria (>0.5 g/day) - Less effective if proteinuria already suppressed - Personalize based on proteinuria level and progression rate

FGF23 Pathway Inhibitors (Emerging)

Rationale: - FGF23 elevated in CKD; contributes to mineral metabolism disorders and cardiovascular events - FGF23 pathway blockade may slow CKD progression

Agents in Development: - Pegcetacoplan (C3i): Incidental benefit on FGF23 - FGF23 antibodies: Direct blockade (early trials) - FGFR inhibitors: Block downstream signaling (preclinical)

Status: Mostly research; not yet clinically available

Application of Algorithms to CKD Prognosis

Clinical Challenge: - Current eGFR-albuminuria categories are imperfect - 20–30% of patients progress to ESRD despite seemingly “low-risk” albuminuria levels - Individual variability in progression rate high

AI/ML Approach: - Train algorithms on large cohorts (e.g., UK Biobank, KDIGO registries) - Input: Demographics, comorbidities, labs (creatinine, cystatin C, albuminuria, labs), biomarkers - Output: Individualized risk score for progression (e.g., “40% risk of 50% GFR decline in 5 years”)

Machine Learning Models in CKD

Prognostic Models Published:

1. KDIGO/KDSC CKD Risk Validator (2021):
   • Web-based risk calculator
   • Inputs: Baseline eGFR, albuminuria, age, sex
   • Outputs: Risk of progression to Stage 4, Stage 5, or composite
2. CKD Prognosis Consortium Models:
   • Developed from meta-analysis of multiple CKD cohorts
   • Incorporates genetic risk scores (polygenic), biomarkers
   • Predicts progression risk stratified by baseline albuminuria
3. Deep Learning Models (Emerging):
   • Neural networks trained on large EHR datasets
   • Incorporate temporal patterns (rate of GFR change over time)
   • Show improved discrimination vs. traditional models in some studies

Practical Integration into Practice

Workflow: 1. Calculate baseline risk: Use KDIGO calculator or CKD consortium tool 2. Gather additional biomarkers: If available (suPAR, NGAL, genetic data) 3. Feed into ML model: Generates individualized risk score 4. Counsel patient: “Your risk of reaching dialysis in 10 years is 25% with current therapy; with aggressive management (intensive BP/glucose control, SGLT2i, etc.), risk decreases to 12%” 5. Tailor therapy: Intensity of treatment matched to predicted risk

Example Clinical Scenario: - 55-year-old with CKD Stage 3a (eGFR 48), albuminuria 500 mg/day, diabetes - KDIGO calculator: 15% risk Stage 4 in 5 years - ML model incorporating NGAL level (high) and genetic risk score (high): 35% risk - Clinical decision: Intensify therapy (SGLT2i + GLP-1 agonist + atrasentan)

Limitations & Considerations

Data Quality Issues: - AI models perform poorly on patients from groups underrepresented in training data - Risk of perpetuating health disparities if not carefully validated across populations

Overfitting: - Models may capture spurious associations rather than true causal relationships - External validation on independent cohorts critical

Clinical Judgment: - AI supports but does not replace clinical decision-making - Patient preferences, comorbidities, life expectancy must be considered alongside risk predictions